Loading...

Lixte Biotechnology Holdings

OTCPK:LIXT
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LIXT
OTCPK
$74M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The last earnings update was 15 days ago. More info.


Add to Portfolio Compare Print
  • Lixte Biotechnology Holdings has significant price volatility in the past 3 months.
LIXT Share Price and Events
7 Day Returns
0.9%
OTCPK:LIXT
1%
US Biotechs
0.2%
US Market
1 Year Returns
753.8%
OTCPK:LIXT
-4.6%
US Biotechs
2.9%
US Market
LIXT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lixte Biotechnology Holdings (LIXT) 0.9% 38.8% 30.6% 753.8% 593.8% 404.5%
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • LIXT outperformed the Biotechs industry which returned -4.6% over the past year.
  • LIXT outperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
LIXT
Industry
5yr Volatility vs Market
Related Companies

LIXT Value

 Is Lixte Biotechnology Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Lixte Biotechnology Holdings. This is due to cash flow or dividend data being unavailable. The share price is $1.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lixte Biotechnology Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lixte Biotechnology Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:LIXT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.04
OTCPK:LIXT Share Price ** OTCPK (2019-05-23) in USD $1.11
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lixte Biotechnology Holdings.

OTCPK:LIXT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:LIXT Share Price ÷ EPS (both in USD)

= 1.11 ÷ -0.04

-31.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lixte Biotechnology Holdings is loss making, we can't compare its value to the US Biotechs industry average.
  • Lixte Biotechnology Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Lixte Biotechnology Holdings's expected growth come at a high price?
Raw Data
OTCPK:LIXT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -31.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Lixte Biotechnology Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lixte Biotechnology Holdings's assets?
Raw Data
OTCPK:LIXT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.00
OTCPK:LIXT Share Price * OTCPK (2019-05-23) in USD $1.11
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
OTCPK:LIXT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:LIXT Share Price ÷ Book Value per Share (both in USD)

= 1.11 ÷ 0.00

354.41x

* Primary Listing of Lixte Biotechnology Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lixte Biotechnology Holdings is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Lixte Biotechnology Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Lixte Biotechnology Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LIXT Future Performance

 How is Lixte Biotechnology Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lixte Biotechnology Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lixte Biotechnology Holdings expected to grow at an attractive rate?
  • Unable to compare Lixte Biotechnology Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Lixte Biotechnology Holdings's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Lixte Biotechnology Holdings's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:LIXT Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:LIXT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:LIXT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -1 -2
2018-12-31 -2 -2
2018-09-30 -1 -2
2018-06-30 -2 -2
2018-03-31 -2 -2
2017-12-31 -1 -2
2017-09-30 -2 -2
2017-06-30 -2 -2
2017-03-31 -2 -2
2016-12-31 -2 -2
2016-09-30 0 -2 -2
2016-06-30 0 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Lixte Biotechnology Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Lixte Biotechnology Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:LIXT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Lixte Biotechnology Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:LIXT Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.04
2018-12-31 -0.04
2018-09-30 -0.04
2018-06-30 -0.03
2018-03-31 -0.03
2017-12-31 -0.03
2017-09-30 -0.04
2017-06-30 -0.04
2017-03-31 -0.05
2016-12-31 -0.04
2016-09-30 -0.05
2016-06-30 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lixte Biotechnology Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Lixte Biotechnology Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Lixte Biotechnology Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Lixte Biotechnology Holdings's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Lixte Biotechnology Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lixte Biotechnology Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LIXT Past Performance

  How has Lixte Biotechnology Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lixte Biotechnology Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lixte Biotechnology Holdings does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Lixte Biotechnology Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Lixte Biotechnology Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Lixte Biotechnology Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lixte Biotechnology Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:LIXT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -2.18 2.13 0.06
2018-12-31 -2.13 2.10 0.04
2018-09-30 -2.22 2.05 0.17
2018-06-30 -1.65 1.27 0.38
2018-03-31 -1.57 1.22 0.35
2017-12-31 -1.81 1.34 0.47
2017-09-30 -1.89 1.38 0.51
2017-06-30 -2.08 1.63 0.45
2017-03-31 -2.34 1.59 0.75
2016-12-31 -2.13 1.26 0.87
2016-09-30 0.20 -2.23 1.04 1.39
2016-06-30 0.20 -2.37 0.68 1.88
2016-03-31 0.20 -2.31 0.66 1.85
2015-12-31 0.20 -2.85 0.75 2.09
2015-09-30 -2.83 0.97 1.73
2015-06-30 -2.55 1.01 1.41
2015-03-31 -2.80 0.98 1.46
2014-12-31 -2.77 1.29 1.12
2014-09-30 -2.53 1.04 1.05
2014-06-30 -2.34 0.94 0.96
2014-03-31 -1.97 0.88 0.88
2013-12-31 -1.37 0.49 0.88
2013-09-30 -1.29 0.53 0.76
2013-06-30 -2.96 0.88 0.94
2013-03-31 -3.32 0.94 0.90
2012-12-31 -3.58 1.09 1.01
2012-09-30 -3.97 1.13 1.37
2012-06-30 -2.70 0.82 1.34

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Lixte Biotechnology Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Lixte Biotechnology Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Lixte Biotechnology Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Lixte Biotechnology Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lixte Biotechnology Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LIXT Health

 How is Lixte Biotechnology Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lixte Biotechnology Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lixte Biotechnology Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Lixte Biotechnology Holdings has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lixte Biotechnology Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Lixte Biotechnology Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lixte Biotechnology Holdings Company Filings, last reported 1 month ago.

OTCPK:LIXT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 3.71 0.00 3.89
2018-12-31 4.13 0.00 4.27
2018-09-30 -0.01 0.00 0.37
2018-06-30 0.24 0.00 0.54
2018-03-31 0.62 0.00 0.81
2017-12-31 1.00 0.00 1.31
2017-09-30 1.39 0.00 1.59
2017-06-30 1.82 0.00 2.03
2017-03-31 0.67 0.00 0.87
2016-12-31 0.21 0.00 0.20
2016-09-30 0.74 0.00 0.67
2016-06-30 1.24 0.00 1.15
2016-03-31 1.03 0.00 0.97
2015-12-31 0.31 0.00 0.13
2015-09-30 0.80 0.00 0.74
2015-06-30 1.33 0.00 1.25
2015-03-31 1.43 0.00 1.46
2014-12-31 0.27 0.00 0.26
2014-09-30 0.59 0.00 0.90
2014-06-30 0.98 0.00 1.24
2014-03-31 -0.10 0.09 0.12
2013-12-31 0.24 0.00 0.48
2013-09-30 0.58 0.09 0.80
2013-06-30 0.88 0.09 1.08
2013-03-31 1.21 0.09 1.38
2012-12-31 1.49 0.09 1.66
2012-09-30 1.72 0.09 1.89
2012-06-30 1.90 0.09 2.18
  • Lixte Biotechnology Holdings has no debt.
  • Lixte Biotechnology Holdings currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Lixte Biotechnology Holdings has sufficient cash runway for 2.8 years based on current free cash flow.
  • Lixte Biotechnology Holdings has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -11.6% each year.
X
Financial health checks
We assess Lixte Biotechnology Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lixte Biotechnology Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LIXT Dividends

 What is Lixte Biotechnology Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lixte Biotechnology Holdings dividends.
If you bought $2,000 of Lixte Biotechnology Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lixte Biotechnology Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lixte Biotechnology Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:LIXT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lixte Biotechnology Holdings has not reported any payouts.
  • Unable to verify if Lixte Biotechnology Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lixte Biotechnology Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lixte Biotechnology Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Lixte Biotechnology Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lixte Biotechnology Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lixte Biotechnology Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LIXT Management

 What is the CEO of Lixte Biotechnology Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Kovach
COMPENSATION $60,000
AGE 81
CEO Bio

Dr. John S. Kovach, M.D, founded Lixte Biotechnology Holdings, Inc. in August 2005 and serves as its Chairman, Chief Executive Officer, President, Principal Financial Officer. From 1994 to 2000, Dr. Kovach served as an Executive Vice President of Medical and Scientific Affairs, City of Hope National Medical Center in Los Angeles, California. From 1976 to 1994, he served as a Consultant in Oncology and a Director of the Cancer Pharmacology Division at the Mayo Clinic in Rochester, Minnesota. During this time, he directed the early clinical trials program for evaluation of new anti-cancer drugs as principal investigator of contracts from the National Cancer Institute. Dr. Kovach trained in Internal Medicine and Hematology at Presbyterian Hospital, Columbia University and spent six years in the laboratory of Chemical Biology, National Institute of Arthritis and Metabolic diseases studying control of gene expression in bacterial systems. Dr. Kovach was recruited to Stony Brook University in 2000 to found the Long Island Cancer Center (now named the Stony Brook University Cancer Center). From 1986 to 1994, Dr. Kovach served as also Chairman of the Department of Oncology. He served as a Director of Lixte. He also served as a Director of the Beckman Research Center at City of Hope. He served as a Director of the NCI-designated Mayo Comprehensive Cancer Center from 1986 to 1994. Dr. Kovach was a Member of the Arnold and Mabel Beckman Scientific Advisory Board in Newport Beach, California. He has published over 100 articles on the pharmacology , toxicity and effectiveness of anti-cancer treatments and on the molecular epidemiology of breast cancer. Dr. Kovach received a BA from Princeton University and an MD (AOA) from the College of Physicians & Surgeons, Columbia University.

CEO Compensation
  • John's compensation has been consistent with company performance over the past year, both up more than 20%.
  • John's remuneration is lower than average for companies of similar size in United States of America.
Management Team

John Kovach

TITLE
Founder
COMPENSATION
$60K
AGE
81

Gil Schwartzberg

TITLE
Consultant

Francis Johnson

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the Lixte Biotechnology Holdings board of directors in years:

3
Average Tenure
69.5
Average Age
  • The tenure for the Lixte Biotechnology Holdings board of directors is about average.
Board of Directors

Iwao Ojima

TITLE
Member of Scientific Advisory Committee

John Kovach

TITLE
Founder
COMPENSATION
$60K
AGE
81

Philip Palmedo

TITLE
Director
AGE
84
TENURE
12.9 yrs

Dan Von Hoff

TITLE
Member of Scientific Advisory Committee
AGE
70
TENURE
5.3 yrs

Stephen Forman

TITLE
AGE
69
TENURE
3 yrs

Yun Yen

TITLE
Director
COMPENSATION
$52K
AGE
63
TENURE
0.8 yrs

Winson Ho

TITLE
Director
COMPENSATION
$52K
AGE
33
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Dec 18 Buy Jane Riggs Individual 07. Dec 18 07. Dec 18 630,000 $0.50 $315,000
12. Dec 18 Buy Arthur Riggs Individual 07. Dec 18 07. Dec 18 630,000 $0.50 $315,000
12. Dec 18 Buy Gil Schwartzberg Individual 07. Dec 18 07. Dec 18 1,040,000 $0.50 $520,000
12. Dec 18 Buy Philip Palmedo Individual 07. Dec 18 07. Dec 18 100,000 $0.50 $50,000
12. Dec 18 Buy Stephen Forman Individual 07. Dec 18 07. Dec 18 100,000 $0.50 $50,000
X
Management checks
We assess Lixte Biotechnology Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lixte Biotechnology Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LIXT News

Simply Wall St News

LIXT Company Info

Description

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primary focuses on developing various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gaucher’s disease; and depression and post-traumatic stress syndrome. It develops protein phosphatase inhibitors that include LB-100 series of compounds; and histone deacetylase inhibitors, which comprises LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases, which are under various stages of pre-clinical and clinical developments. The company was founded in 2005 and is based in East Setauket, New York.

Details
Name: Lixte Biotechnology Holdings, Inc.
LIXT
Exchange: OTCPK
Founded: 2005
$74,420,853
67,045,814
Website: http://www.lixte.com
Address: Lixte Biotechnology Holdings, Inc.
248 Route 25A, No. 2,
East Setauket,
New York, 11733,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK LIXT Common Stock Pink Sheets LLC US USD 21. Sep 2007
Number of employees
Current staff
Staff numbers
0
Lixte Biotechnology Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 00:05
End of day share price update: 2019/05/23 00:00
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.